National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

You disconnect your cell phone from its charger as you get ready for a busy day. But even though it has been connected all night, the battery is only partially charged. You look at ...

A new study suggests that a simple treatment algorithm could significantly reduce disparities in multiple sclerosis care ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says ...

An immune profile consistent with the eactivation of the Epstein-Barr virus was observed in MS patients prior to a disease ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS) ...

3%-5% of individuals with MS experience symptoms before age 18 years. Identifying potential risk factors for relapse is important in individuals with pediatric MS, who have higher relapse rates ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

Thousands of NHS patients in England with multiple sclerosis (MS) will soon be offered a "take at home" tablet to manage ...

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...